Brief: Addex Starts Phase 2 Clinical Study Of ADX71149 For Epilepsy
June 7 (Reuters) - ADDEX THERAPEUTICS LTD ADXN.S :
* STARTS PHASE 2 CLINICAL STUDY OF ADX71149 FOR EPILEPSY
* DATA FROM STUDY ARE EXPECTED IN Q3 2022
Source text for Eikon: ID:nGNEbp6FBc
Further company coverage: ADXN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Addex Therapeutics
See all newsBrief: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia
NASDAQ RESUMED AT 11:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:24 AM
Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses
Brief: Addex Therapeutics Q2 Operating Income CHF -645 Thousand